patients preferences for adjuvant therapy of malignant melanoma

Conditions: C43.9
Malignant melanoma of skin, unspecified

Registration Number: DRKS00031706

Lead Sponsor: niversitätsmedizin Göttingen

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: Pending

Sex: All

Target Recruitment: 500

Inclusion Criteria

Presence of malignant melanoma in AJCC stage IIB, IIC, IIIA, IIIB, IIIC or IIID
- Diagnosis made within the last 5 years or stage transition to one of the aforementioned stages within the last 5 years
- Age =18 years
- Adjuvant therapy situation, but independent of current or previous therapy
- Ability to understand the Discrete Choice Experiments
- Capacity to consent
- Written consent to participate in the study

Exclusion Criteria

Excluded from participating the study are the investigators themselves and members of the study team who directly or indirectly participate in conducting the study.

Study & Design

Study Type: observational

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
The primary outcome of the clincal study is the patients' preferences for the different options of adjuvant therapy based on the attributes that are captured in the questionnaire. These attributes include the risk of recurrence within a year, typical adverse effects, the risk of severe adverse effects, that impair well-being severly or longterm or require hospitalization, as well as application form and frequency of the treatment (oral therapy vs. intravenous infusions).

Secondary Outcome Measures

Name	Time	Method
The secondary outcome is the investigation of sociodemographic, socioeconomic and clinical characterics that may influence the patients' preferences for adjuvant therapy. Especially the relevance of age, sex, education, income, disease-related characteristics and comorbidities for the decision-making process will be discussed.